呼吸器疾患ワクチン市場- 世界の産業規模、シェア、動向、機会、予測、タイプ別、感染症別、流通チャネル別、地域別、競合別、2020～2030年

世界の呼吸器疾患ワクチン市場は2024年に946億米ドルと評価され、2030年までのCAGRは1.15%で、予測期間中に目覚ましい成長を遂げると予測されています。

呼吸器疾患は、呼吸器障害または肺疾患としても知られ、呼吸器系に影響を及ぼす医学的状態の広範なカテゴリーを包含します。推定20億人がバイオマス燃料の消費による有害な影響を受け、10億人が屋外の大気汚染にさらされ、さらに10億人がタバコの煙の影響を受けています。これらの環境要因や生活習慣は、慢性呼吸器疾患による年間約400万人の早期死亡の原因となっています。呼吸器系には、呼吸、酸素交換、二酸化炭素除去を担う器官や構造が含まれます。呼吸器系に関与する主要な器官は肺であるが、気道や筋肉などの他の構成要素も重要な役割を果たしています。呼吸器疾患は、細菌、ウイルス、真菌など様々な感染因子によって引き起こされます。インフルエンザや肺炎のほか、呼吸器感染症には気管支炎、気管支炎、結核などがあります。アレルギー性鼻炎（花粉症）やアレルギー性喘息などのアレルギー性疾患は、花粉、ダニ、動物の危険などのアレルゲンに対する免疫反応が関与しています。これらの疾患は、くしゃみ、鼻水、喘鳴などの呼吸器症状を引き起こします。職場や環境中の有害物質への暴露は、呼吸器疾患を引き起こす可能性があります。例えば、アスベスト関連肺疾患、石炭労働者じん肺症（黒色肺疾患）、職業性喘息などが挙げられます。

世界の高齢化により、呼吸器疾患のリスクが高まっています。高齢者人口の増加に伴い、この脆弱な集団を保護するワクチンの必要性が高まっています。世界の政府やヘルスケア機関は、インフルエンザなど特定の呼吸器疾患に対するワクチン接種を推奨または義務付けています。このような推奨が、ワクチンの普及と接種率を押し上げています。COVID-19パンデミックの際に見られたような新たな呼吸器系ウイルスの出現は、ワクチン接種による備えの重要性を浮き彫りにしています。政府や組織は、パンデミック対応計画の重要な一部としてワクチンに投資しています。公衆衛生キャンペーンやイニシアチブは、ワクチン接種を促進し、呼吸器疾患ワクチンの利点についての認識を高める。このような努力は、ワクチンの接種率を高めることを目的としています。世界保健機関（WHO）やユニセフのような国際機関は、低・中所得国におけるワクチン接種機会の拡大に取り組んでいます。世界の予防接種プログラムは、呼吸器疾患の負担軽減を目指しています。

主な市場促進要因

呼吸器疾患の有病率の増加

高齢化人口の増加

ワクチンの義務化と推奨

世界の予防接種プログラム

主な市場課題

ワクチン嫌いと誤った情報

サプライチェーンの混乱

主要市場動向

肺炎球菌ワクチン

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の呼吸器疾患ワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別（ウイルスワクチン、細菌ワクチン、混合ワクチン）
  • 感染症別（COVID-19、インフルエンザ、RSウイルス（RSV）、肺炎、その他）
  • 流通チャネル別（病院・薬局、政府系サプライヤー、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 アジア太平洋地域の呼吸器疾患ワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 感染症別
  • 流通チャネル別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • オーストラリア
  • 日本
  • 韓国

第7章 欧州の呼吸器疾患ワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 感染症別
  • 流通チャネル別
  • 国別
• 欧州：国別分析
  • フランス
  • ドイツ
  • スペイン
  • イタリア
  • 英国

第8章 北米の呼吸器疾患ワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 感染症別
  • 流通チャネル別
  • 国別
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第9章 南米の呼吸器疾患ワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 感染症別
  • 流通チャネル別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの呼吸器疾患ワクチン市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • タイプ別
  • 感染症別
  • 流通チャネル別
  • 国別
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界の呼吸器疾患ワクチン市場：SWOT分析

第14章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第15章 PESTEL分析

第16章 競合情勢

• GSK plc.
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• Sanofi SA
• Serum Institute of India Pvt. Ltd.
• Sinovac Biotech Ltd.
• Bavarian Nordic A/S
• Merck & Co., Inc.
• AstraZeneca Plc.
• Moderna Inc.

第17章 戦略的提言

第18章 調査会社について・免責事項

Global Respiratory Disease Vaccine Market was valued at USD 94.60 Billion in 2024 and is anticipated to witness an impressive growth in the forecast period with a CAGR of 1.15% through 2030. Respiratory diseases, also known as respiratory disorders or lung diseases, encompass a broad category of medical conditions that affect the respiratory system. An estimated 2 billion individuals are subjected to the harmful impacts of biomass fuel consumption, while 1 billion face exposure to outdoor air pollution, and another 1 billion are affected by tobacco smoke. These environmental and lifestyle factors contribute to the premature death of approximately 4 million people annually due to chronic respiratory diseases. The respiratory system includes the organs and structures responsible for breathing, oxygen exchange, and carbon dioxide removal. The primary organs involved in the respiratory system are the lungs, but other components, such as the airways and muscles, also play crucial roles. Respiratory diseases can be caused by various infectious agents, including bacteria, viruses, and fungi. In addition to the flu and pneumonia, other respiratory infections include bronchitis, bronchiolitis, and tuberculosis. Allergic conditions, such as allergic rhinitis (hay fever) and allergic asthma, involve an immune response to allergens like pollen, dust mites, and animal danger. These conditions can lead to respiratory symptoms like sneezing, runny nose, and wheezing. Exposure to harmful substances in the workplace or environment can lead to respiratory diseases. Examples include asbestos-related lung diseases, coal worker's pneumoconiosis (black lung disease), and occupational asthma.

The global aging population is at a higher risk of respiratory diseases. As the elderly population grows, there is a greater need for vaccines to protect this vulnerable group. Government and healthcare organizations worldwide recommend or mandate vaccinations for certain respiratory diseases, such as influenza. These recommendations drive vaccine adoption and coverage rates. The emergence of new respiratory viruses, as witnessed during the COVID-19 pandemic, highlights the importance of preparedness through vaccination. Governments and organizations invest in vaccines as a key part of pandemic response plans. Public health campaigns and initiatives promote vaccination and raise awareness about the benefits of respiratory disease vaccines. These efforts aim to increase vaccine uptake. International organizations like the World Health Organization (WHO) and UNICEF work to expand vaccination access in low- and middle-income countries. Global immunization programs aim to reduce the burden of respiratory diseases.

Key Market Drivers

Increasing Prevalence of Respiratory Diseases

The increasing prevalence of respiratory diseases plays a pivotal role in driving the growth of the Global Respiratory Disease Vaccine Market by creating a sustained demand for preventive healthcare solutions. Respiratory diseases represent a significant global health challenge. Current estimates show that 235 million people are affected by asthma, over 200 million individuals suffer from chronic obstructive pulmonary disease (COPD), and 65 million endure moderate-to-severe COPD. Furthermore, between 1-6% of the adult population, equating to more than 100 million people, experience sleep-disordered breathing. Annually, 8.7 million people develop tuberculosis (TB), while millions contend with pulmonary hypertension. Additionally, more than 50 million individuals are impacted by occupational lung diseases. Collectively, over 1 billion people globally are living with chronic respiratory conditions. This demand is shaped by several interconnected factors, including the rising incidence of respiratory conditions, their economic and healthcare system burden, and the growing public awareness of vaccination as a key preventive strategy.

The growing global burden of respiratory diseases is one of the primary factors driving the market for respiratory disease vaccines. Healthcare expenditures for respiratory diseases are placing an escalating financial strain on economies worldwide. In the United States alone, the annual economic burden of asthma is estimated at USD18 billion. This trend reflects the growing cost of managing respiratory conditions, further highlighting the urgent need for effective prevention and treatment strategies. Diseases such as influenza, pneumonia, chronic obstructive pulmonary disease (COPD), and respiratory syncytial virus (RSV) infections are increasingly common, particularly in vulnerable populations like the elderly and individuals with underlying health conditions. The rise in these conditions directly translates to a heightened demand for vaccines aimed at preventing or reducing the severity of these diseases. The seasonal nature of influenza outbreaks, which can lead to widespread illness, hospitalizations, and even death, results in consistent demand for influenza vaccines annually. With pneumonia being one of the leading causes of death worldwide, especially among the elderly, vaccination campaigns targeting pneumonia have gained prominence. Chronic obstructive pulmonary disease (COPD) ranks as the fourth leading cause of death globally, with incidence rates continuing to rise. Lung cancer, the most prevalent fatal cancer worldwide, claims the lives of over 1.4 million individuals annually, and its mortality rate is also on the rise. Respiratory infections caused by influenza result in 250,000 to 500,000 deaths each year, while also imposing an economic burden of approximately 71 to 167 billion US dollars annually. As the prevalence of chronic respiratory diseases like COPD rises, particularly due to smoking and environmental factors, the need for vaccines to prevent infections that exacerbate such conditions grows. Infections caused by RSV are significant among infants and the elderly, driving demand for vaccines that can protect these high-risk groups. The increasing prevalence of respiratory diseases places a significant burden on healthcare systems worldwide. Hospitalizations, long-term care, and the overall costs associated with treating respiratory conditions create a financial and operational strain on public health systems. In response, governments and healthcare organizations are focusing on prevention strategies, with vaccination being a key pillar of this approach. Vaccines reduce the incidence of severe disease and hospital admissions, thereby alleviating pressure on healthcare facilities and reducing treatment costs. This economic incentive pushes both public and private healthcare stakeholders to invest in and promote respiratory disease vaccines as a primary solution.

Respiratory diseases tend to follow seasonal patterns, such as the annual flu season, leading to periodic surges in cases. The continuous nature of these outbreaks, exacerbated by factors like climate change and the movement of populations, means that the demand for vaccines is consistently high. Governments and organizations, particularly in countries with temperate climates, invest heavily in seasonal vaccination programs to control outbreaks and prevent large-scale public health crises. Moreover, endemic outbreaks of diseases like RSV in certain regions also spur local and international vaccination efforts. The need for vaccines to control such outbreaks and prevent the spread of infections in communities drives market growth. The increasing prevalence of respiratory diseases is closely linked to the aging global population. Older adults are more susceptible to respiratory infections and often experience more severe outcomes, including hospitalization or death. This demographic shift amplifies the demand for vaccines designed to protect against common respiratory pathogens, particularly influenza and pneumonia. With aging populations in regions such as Europe, North America, and parts of Asia, governments are increasingly focused on improving vaccination coverage in this high-risk group. This has led to an uptick in both the volume of vaccines administered and the types of vaccines available, including those targeted specifically at the elderly.

The rising prevalence of respiratory diseases results in significant indirect costs, including lost productivity due to illness, premature mortality, and long-term disability. As respiratory diseases become more widespread, these economic burdens grow, encouraging governments and organizations to invest in preventive measures such as vaccination programs. The financial strain on businesses due to employee absenteeism or decreased productivity from sick workers further emphasizes the importance of respiratory disease prevention through vaccination. As businesses and insurance companies look to reduce the financial impact of respiratory diseases, they advocate for increased vaccination coverage among their employees and policyholders. With the growing awareness of the detrimental effects of respiratory diseases, particularly in light of the COVID-19 pandemic, there is a noticeable shift in public attitudes towards preventive healthcare. People are more inclined to seek out vaccines as a means to reduce the risk of respiratory infections. This trend, coupled with widespread education campaigns, boosts the demand for respiratory disease vaccines. Governments, healthcare organizations, and pharmaceutical companies actively promote vaccination as a cost-effective, long-term solution to managing the growing prevalence of respiratory diseases. The global trend toward healthier lifestyles and preventive measures further strengthens the market for vaccines.

Rising Aging Population

Elderly individuals are more susceptible to respiratory diseases and complications. By 2030, one in six people globally will be aged 60 or older, with the number of individuals in this age group increasing from 1 billion in 2020 to 1.4 billion. By 2050, the global population of those aged 60 and above is projected to double to 2.1 billion. Additionally, the number of individuals aged 80 or older is expected to triple between 2020 and 2050, reaching 426 million. As people age, their immune systems may weaken, making them more prone to infections like influenza, pneumonia, and respiratory syncytial virus (RSV). This increased vulnerability drives the need for vaccines to protect older adults. Respiratory diseases can be more severe in older adults, leading to higher hospitalization rates and mortality. Vaccines are essential for preventing these severe outcomes in the elderly population. During influenza and other respiratory disease outbreaks, the elderly are often at higher risk. Aging is the primary demographic risk factor for idiopathic pulmonary fibrosis (IPF). Similarly, the prevalence of chronic obstructive pulmonary disease (COPD) is reported to be two to three times higher among individuals over the age of 60. The ongoing global trend of an aging population is contributing significantly to the rising incidence of these respiratory diseases. Vaccinating this age group is crucial for epidemic control and reducing the overall disease burden. Pneumococcal vaccines, which protect against pneumonia and other infections caused by Streptococcus pneumoniae bacteria, are recommended for older adults. These vaccines play a vital role in preventing pneumococcal diseases.

Vaccinating the elderly is a public health strategy to reduce the societal and economic impact of respiratory diseases. It helps in lowering healthcare costs associated with disease treatment and hospitalizations. By vaccinating older adults, it not only protects them but also contributes to herd immunity. This indirectly benefits younger age groups and individuals who may not be able to receive vaccines due to medical contraindications. As life expectancy increases in many parts of the world, the elderly population becomes a more significant proportion of the total population. This demographic shift further underscores the importance of vaccination to maintain health and quality of life in older age. The demand for respiratory disease vaccines for the elderly population incentivizes pharmaceutical companies to invest in research and development to create more effective and targeted vaccines for this demographic. This factor will help in the development of the Global Respiratory Disease Vaccine Market.

Vaccine Mandates and Recommendations

Some governments and institutions have implemented vaccine mandates, requiring individuals to receive specific respiratory disease vaccines. For example, healthcare workers may be required to receive annual influenza vaccinations to reduce the risk of spreading the virus to vulnerable patients. In many countries, children are required to receive certain vaccinations before enrolling in schools or daycare centers. This includes vaccines for diseases like measles, mumps, rubella, and sometimes influenza. Such requirements ensure high vaccine coverage among school-age children. Some countries may require proof of vaccination against certain respiratory diseases, such as tuberculosis or COVID-19, for travelers or immigrants. These requirements aim to prevent the spread of diseases across borders. Certain professions, such as healthcare, may have vaccine mandates to protect both workers and patients. For example, healthcare facilities may require employees to receive vaccines against influenza, hepatitis B, or other respiratory diseases. Government health agencies and organizations like the World Health Organization (WHO) provide recommendations for vaccination against respiratory diseases. These recommendations encourage healthcare providers to offer vaccines to eligible individuals and the general population.

Health authorities often run public health campaigns to promote vaccination against respiratory diseases, particularly during flu seasons. These campaigns raise awareness about the importance of vaccination and recommend vaccination to specific populations, such as pregnant women and the elderly. During outbreaks or epidemics of respiratory diseases, health authorities may recommend or mandate vaccination to control the spread of the disease. For example, during the H1N1 influenza pandemic, vaccination campaigns were widely promoted. Recommendations often target high-risk groups, such as the elderly, young children, pregnant women, and individuals with underlying health conditions. These individuals are more susceptible to severe respiratory diseases, making vaccination crucial. Recommendations and mandates can facilitate access to vaccines by making them readily available in healthcare settings, including hospitals, clinics, and pharmacies. Encouraging vaccination in the community helps achieve herd immunity, protecting those who cannot be vaccinated due to medical reasons or contraindications. Health authorities may use epidemiological data and research to make evidence-based recommendations and mandates. These decisions are often informed by disease prevalence and severity. This factor will pace up the demand of the Global Respiratory Disease Vaccine Market.

Global Immunization Programs

Global immunization programs aim to ensure equitable access to vaccines for people in low- and middle-income countries, as well as underserved populations within high-income countries. This access extends to respiratory disease vaccines, such as those for influenza and pneumonia. These programs strive to achieve high vaccination coverage rates, including coverage for respiratory diseases. The goal is to protect as many individuals as possible against preventable respiratory infections. In response to global health threats like pandemics (e.g., COVID-19), international organizations and governments work to develop vaccination strategies and distribute vaccines on a global scale. This preparedness includes respiratory disease vaccines for pandemic control. By focusing on the prevention of respiratory diseases through vaccination, global immunization programs aim to reduce the overall burden of these diseases, including hospitalizations and mortality. Immunization programs often include targeted campaigns for specific age groups, populations at higher risk, and those in humanitarian settings. These campaigns raise awareness about respiratory disease vaccines and encourage vaccination.

Global immunization efforts include strengthening vaccine supply chains to ensure vaccines, including those for respiratory diseases, reach even the most remote and resource-limited areas. Investment in research and development of new and improved respiratory disease vaccines is often a component of these programs. This fosters innovation and the availability of more effective vaccines. Building the capacity of healthcare systems and providers in vaccine administration and surveillance is part of global immunization programs. This ensures the effective delivery of respiratory disease vaccines. Collaborations between governments, international organizations, and private-sector vaccine manufacturers are common in global immunization programs. These partnerships enhance vaccine production, affordability, and accessibility. Education and training initiatives are integral to global immunization programs. They equip healthcare workers and communities with knowledge about the importance of respiratory disease vaccination. In times of crises, such as outbreaks or natural disasters, global immunization programs can quickly mobilize resources and vaccines to protect vulnerable populations from respiratory diseases. Robust monitoring and surveillance systems are established to track vaccine coverage, adverse events, and disease trends. Data collection informs program adjustments and vaccine distribution. This factor will accelerate the demand of the Global Respiratory Disease Vaccine Market.

Key Market Challenges

Vaccine Hesitancy and Misinformation

Vaccine hesitancy, characterized by reluctance or refusal to receive vaccines, can lead to lower vaccination rates. When a substantial portion of the population remains unvaccinated, it leaves communities vulnerable to respiratory diseases, including influenza, pneumonia, and COVID-19. Achieving herd immunity, where a sufficient percentage of the population is immune to a disease, is crucial for protecting those who cannot be vaccinated, such as individuals with medical contraindications. Vaccine hesitancy can hinder efforts to reach herd immunity and indirectly impact vulnerable individuals. When vaccination rates drop due to hesitancy, it can lead to the resurgence of preventable respiratory diseases. Outbreaks of vaccine-preventable diseases, like measles, have occurred in areas with low vaccine coverage. Lower vaccination rates can result in increased disease transmission and outbreaks, leading to public health crises. This places additional strain on healthcare systems and resources. Misinformation and disinformation about vaccines, often spread through social media and other channels, can lead to false beliefs and fears about vaccine safety and efficacy. This can erode public trust in vaccines and healthcare authorities. Concerns about vaccine side effects, whether founded or unfounded, can contribute to hesitancy. Misinformation can amplify fears and discourage vaccination. During pandemics, like the COVID-19 pandemic, vaccine hesitancy can slow down efforts to achieve widespread vaccination coverage, making it challenging to control the spread of the virus and save lives. Persistent vaccine hesitancy can erode public confidence in the entire vaccination process and the healthcare system. This can have long-term repercussions for public health.

Supply Chain Disruptions

Disruptions in the supply chain, such as interruptions in the availability of raw materials, can lead to delays in vaccine production. This can result in vaccine shortages and affect the ability to meet demand. Supply chain disruptions can affect the timely distribution of vaccines to healthcare facilities, clinics, and pharmacies. This can lead to logistical challenges and difficulties in ensuring that vaccines reach the intended recipients. Supply chain disruptions can result in vaccines being wasted if they cannot be stored or transported properly. Temperature-sensitive vaccines, like some respiratory disease vaccines, are particularly vulnerable to wastage if cold chain integrity is compromised. Interruptions in the supply chain can impact the ability to provide vaccines to underserved regions, especially in low- and middle-income countries. This can exacerbate global health inequalities. During pandemics, like the COVID-19 pandemic, ensuring a consistent and uninterrupted supply chain for vaccines is critical. Any disruptions can slow down vaccination efforts and hinder the control of the disease's spread. Supply chain disruptions can affect the capacity of vaccine manufacturers to produce vaccines at scale. This can impact their ability to meet the demand for respiratory disease vaccines. Shortages of key raw materials, such as vials, adjuvants, and specialized equipment, can disrupt vaccine production and lead to bottlenecks in the supply chain. Transportation disruptions, including delays, restrictions, or interruptions in shipping and logistics, can hinder the movement of vaccines across regions and countries.

Key Market Trends

Pneumococcal Vaccines

Pneumococcal diseases, including pneumonia and invasive pneumococcal diseases (IPD), are associated with significant morbidity and mortality worldwide. These diseases can affect people of all ages, but they are particularly dangerous for young children and the elderly. Many countries recommended pneumococcal vaccination for specific age groups, especially young children, older adults, and individuals with certain underlying medical conditions. These recommendations drove the demand for pneumococcal vaccines. Pneumonia is a leading cause of morbidity and mortality, especially among children and older adults. Pneumococcal vaccines are effective in preventing pneumonia, making them a valuable tool in reducing the disease burden. Advances in vaccine technology led to the development of pneumococcal conjugate vaccines, which offer protection against a broader range of pneumococcal serotypes. These vaccines have been increasingly adopted in vaccination programs. Pneumococcal vaccination has shown a significant reduction in the incidence of pneumococcal diseases, leading to improved public health outcomes and reduced healthcare costs. Pneumococcal vaccines are part of pandemic preparedness efforts, as they can help reduce the burden on healthcare systems during respiratory disease outbreaks.

Segmental Insights

Type Insights

In 2024, the Global Respiratory Disease Vaccine Market largest share was held by viral vaccine segment and is predicted to continue expanding over the coming years. Viral respiratory diseases, such as influenza (flu), respiratory syncytial virus (RSV), and COVID-19, are widespread and have a significant impact on public health. These diseases can cause a wide range of respiratory infections, from mild to severe, and sometimes lead to hospitalizations and fatalities. This high prevalence drives the demand for vaccines to prevent these viral infections. Vaccination against viral respiratory diseases like influenza is a routine part of healthcare in many countries. Seasonal flu vaccination campaigns are conducted annually to protect individuals and prevent the spread of the virus, contributing to the steady demand for viral vaccines. Viral respiratory diseases often disproportionately affect elderly individuals and those with underlying health conditions. Vaccination is recommended for these high-risk groups, further driving demand for viral vaccines.

Distribution Channel Insights

In 2024, the Global Respiratory Disease Vaccine Market largest share was held by hospital and retail pharmacies segment in the forecast period and is predicted to continue expanding over the coming years. Hospitals and retail pharmacies are easily accessible to the general population. Patients often visit hospitals for routine check-ups, treatments, and vaccinations. Retail pharmacies, on the other hand, are widely distributed in urban and rural areas, making them convenient locations for vaccine administration. Healthcare providers, including doctors and nurses, play a crucial role in recommending and administering vaccines. Hospitals are primary healthcare settings where patients receive recommendations for vaccination, and vaccines are administered during hospital visits. Hospitals are frequently used as vaccination centres during large-scale vaccination campaigns organized by governments and healthcare organizations. For example, flu vaccination campaigns often involve hospitals as key distribution points. Respiratory diseases are more common among the elderly population. Many elderly individuals receive healthcare services in hospitals, and hospitals are more likely to have specialized departments for geriatric care, where vaccination is routinely offered.

Regional Insights

The Asia Pacific region held the largest market share in the Global Respiratory Disease Vaccine Market in 2024. The Asia Pacific region is home to a substantial portion of the world's population, including densely populated countries like China and India. The sheer number of people in the region creates a significant market for respiratory disease vaccines. Many countries in the Asia Pacific have been experiencing economic growth, leading to increased healthcare spending. This has allowed for greater investment in healthcare infrastructure, including vaccination programs. Awareness about the importance of vaccination has been on the rise in the Asia Pacific region. Governments and healthcare organizations have been actively promoting immunization, including respiratory disease vaccines, to combat the burden of preventable diseases. Like many other regions, the Asia Pacific is experiencing demographic changes with a growing aging population. Older adults are more susceptible to respiratory diseases, such as influenza and pneumonia, driving the demand for vaccines.

Key Market Players

• GSK plc.
• Johnson & Johnson Services, Inc.
• Pfizer Inc.
• Sanofi SA
• Serum Institute of India Pvt. Ltd.
• SINOVAC Biotech Ltd.
• Bavarian Nordic A/S
• Merck & Co., Inc.
• AstraZeneca Plc.

Report Scope:

In this report, the Global Respiratory Disease Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Respiratory Disease Vaccine Market, By Type:

• Viral Vaccine
• Bacterial Vaccine
• Combination Vaccine

Respiratory Disease Vaccine Market, By Infection:

• COVID-19
• Influenza
• Respiratory Syncytial Virus (RSV)
• Pneumonia
• Others

Respiratory Disease Vaccine Market, By Distribution Channel:

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

Respiratory Disease Vaccine Market, By region:

• North America
  • United States
  • Canada
  • Mexico
• Asia-Pacific
  • China
  • India
  • South Korea
  • Australia
  • Japan
• Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Italy
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Respiratory Disease Vaccine Market.

Available Customizations:

Global Respiratory Disease Vaccine Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Respiratory Disease Vaccine Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Viral Vaccine, Bacterial Vaccine, Combination Vaccine)
  • 5.2.2. By Infection (COVID-19, Influenza, Respiratory Syncytial Virus (RSV), Pneumonia, Others)
  • 5.2.3. By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Respiratory Disease Vaccine Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Infection
  • 6.2.3. By Distribution Channel
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Respiratory Disease Vaccine Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Infection
      • 6.3.1.2.3. By Distribution Channel
  • 6.3.2. India Respiratory Disease Vaccine Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Infection
      • 6.3.2.2.3. By Distribution Channel
  • 6.3.3. Australia Respiratory Disease Vaccine Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Infection
      • 6.3.3.2.3. By Distribution Channel
  • 6.3.4. Japan Respiratory Disease Vaccine Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Infection
      • 6.3.4.2.3. By Distribution Channel
  • 6.3.5. South Korea Respiratory Disease Vaccine Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Infection
      • 6.3.5.2.3. By Distribution Channel

7. Europe Respiratory Disease Vaccine Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Infection
  • 7.2.3. By Distribution Channel
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Respiratory Disease Vaccine Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Infection
      • 7.3.1.2.3. By Distribution Channel
  • 7.3.2. Germany Respiratory Disease Vaccine Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Infection
      • 7.3.2.2.3. By Distribution Channel
  • 7.3.3. Spain Respiratory Disease Vaccine Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Infection
      • 7.3.3.2.3. By Distribution Channel
  • 7.3.4. Italy Respiratory Disease Vaccine Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Infection
      • 7.3.4.2.3. By Distribution Channel
  • 7.3.5. United Kingdom Respiratory Disease Vaccine Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Infection
      • 7.3.5.2.3. By Distribution Channel

8. North America Respiratory Disease Vaccine Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Infection
  • 8.2.3. By Distribution Channel
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Respiratory Disease Vaccine Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Infection
      • 8.3.1.2.3. By Distribution Channel
  • 8.3.2. Mexico Respiratory Disease Vaccine Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Infection
      • 8.3.2.2.3. By Distribution Channel
  • 8.3.3. Canada Respiratory Disease Vaccine Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Infection
      • 8.3.3.2.3. By Distribution Channel

9. South America Respiratory Disease Vaccine Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Infection
  • 9.2.3. By Distribution Channel
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Respiratory Disease Vaccine Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Infection
      • 9.3.1.2.3. By Distribution Channel
  • 9.3.2. Argentina Respiratory Disease Vaccine Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Infection
      • 9.3.2.2.3. By Distribution Channel
  • 9.3.3. Colombia Respiratory Disease Vaccine Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Infection
      • 9.3.3.2.3. By Distribution Channel

10. Middle East and Africa Respiratory Disease Vaccine Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Infection
  • 10.2.3. By Distribution Channel
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Respiratory Disease Vaccine Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Infection
      • 10.3.1.2.3. By Distribution Channel
  • 10.3.2. Saudi Arabia Respiratory Disease Vaccine Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Infection
      • 10.3.2.2.3. By Distribution Channel
  • 10.3.3. UAE Respiratory Disease Vaccine Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Infection
      • 10.3.3.2.3. By Distribution Channel

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Respiratory Disease Vaccine Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. GSK plc.
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Johnson & Johnson Services, Inc.
• 16.3. Pfizer Inc.
• 16.4. Sanofi SA
• 16.5. Serum Institute of India Pvt. Ltd.
• 16.6. Sinovac Biotech Ltd.
• 16.7. Bavarian Nordic A/S
• 16.8. Merck & Co., Inc.
• 16.9. AstraZeneca Plc.
• 16.10.Moderna Inc.

17. Strategic Recommendations

18. About Us & Disclaimer